Immunotherapy has emerged as a key pillar of cancer treatment. To build upon the recent
successes of immunotherapy, intense research efforts are aimed at a molecular …

Targeting immune checkpoints such as programmed cell death protein 1 (PD1),
programmed cell death 1 ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 (CTLA4) has …

Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-
surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) …

The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in
many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within …

Breast cancer rises as the most commonly diagnosed cancer in 2020. Among women,
breast cancer ranks first in both cancer incidence rate and mortality. Treatment resistance …

Purpose: Given that heterogeneous expression and variants of antigens on solid tumors are
responsible for relapse after chimeric antigen receptor (CAR)-T cell therapy, we …

Simple Summary Certain immune cells, namely T cells, of cancer patients can be genetically
manipulated to express so-called chimeric antigen receptors (CARs), which enables these …

By leveraging tumorgraft (patient-derived xenograft) RNA-sequencing data, we developed
an empirical approach, DisHet, to dissect the tumor microenvironment (eTME). We found …

Over the last decades, advances in the knowledge of immunology have led to the
identification of immune checkpoints, reinvigorating cancer immunotherapy. Although …

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer in adults.
When ccRCC is localized to the kidney, surgical resection or ablation of the tumor is often …